Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Novo Nordisk
NYSE:NVO Community
1
Narratives
written by author
0
Comments
on narratives written by author
226
Fair Values set
on narratives written by author
Create a narrative
Novo Nordisk
Popular
Undervalued
Overvalued
Novo Nordisk
BE
Bejgal
Community Contributor
Novo Nordisk will dominate GLP-1 market with Ozempic and Wegovy growth
Catalysts ◦ Strong position in the GLP-1 drug market , leading with Ozempic for diabetes and Wegovy for obesity. These products have driven significant growth.
View narrative
US$85.93
FV
11.7% undervalued
intrinsic discount
18.85%
Revenue growth p.a.
Set as Fair Value
0
users have liked this narrative
0
users have commented on this narrative
24
users have followed this narrative
5 days ago
author updated this narrative
Your Valuation for
NVO
Novo Nordisk
Your Fair Value
US$
Current Price
US$75.89
23.4% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
499b
2015
2018
2021
2024
2025
2027
2030
Revenue DKK 499.2b
Earnings DKK 173.6b
Advanced
Set as Fair Value